VEGF is rapidly cleared from the circulation [14,34], and its tissue half-life is short [35], and so high VEGF doses required to prove therapeutic efficacy were used, which resulted in significant toxicity including hypotension, localized edema, anemia and thrombocytopenia [36,37]. This evidence concerns the gene VEGFA and Thrombocytopenia.